Last reviewed · How we verify
ASKG315
At a glance
| Generic name | ASKG315 |
|---|---|
| Sponsor | AskGene Pharma, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors (PHASE1)
- A Study of ASKG315 in Patients With Advanced Solid Tumors. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASKG315 CI brief — competitive landscape report
- ASKG315 updates RSS · CI watch RSS
- AskGene Pharma, Inc. portfolio CI